PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24284055-3	2014	EXPERIMENTAL DESIGN: SCLC models of HGF-induced EMT were evaluated in vitro and in vivo (subcutaneous xenografts in BALB/c nude mice) for chemosensitivity and response to Met inhibition with PF-2341066 (crizotinib).	Crizotinib	203-213	hepatocyte growth factor	Mus musculus	36-39	
34580063-9	2021	Senescent astrocytes secreted HGF to activate Met in glioma cells and promote their migration and invasion in vitro, which could be blocked by HGF-neutralizing antibodies or the Met inhibitor crizotinib.	Crizotinib	192-202	hepatocyte growth factor	Mus musculus	30-33	
32827692-6	2020	These beneficial effects of HGF were blocked by HGF/c-Met inhibitor Crizotinib or phosphatidylinositide 3-kinases (PI3K) inhibitor LY294002.	Crizotinib	68-78	hepatocyte growth factor	Mus musculus	28-31	
32827692-6	2020	These beneficial effects of HGF were blocked by HGF/c-Met inhibitor Crizotinib or phosphatidylinositide 3-kinases (PI3K) inhibitor LY294002.	Crizotinib	68-78	hepatocyte growth factor	Mus musculus	48-51	
29550255-4	2018	In HER2E cells, hepatocyte growth factor, a ligand for MET, induced resistance that could be reversed with crizotinib, an inhibitor of MET.	Crizotinib	107-117	hepatocyte growth factor	Mus musculus	16-40	
22269210-5	2012	Interestingly, Crizotinib (a dual inhibitor of c-Met and ALK pathways) as single agent or in combination with sunitinib reduced metastasis in all models tested suggesting a role for c-Met/HGF pathway in intrinsic- or sunitinib-induced-metastasis.	Crizotinib	15-25	hepatocyte growth factor	Mus musculus	188-191